cancer from semaglutide Do or Tirzepatide cause thyroid cancer? How Semaglutide May Reduce The

GLP-1 agents help many patients reach that threshold

Ilana Heckler, PhD

Semaglutide targets only the GLP-1 receptor and achieved 14.9% mean weight loss at 68 weeks in the STEP 1 trial

Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with RYBELSUS or OZEMPIC tablets

Patients often report similar appetite suppression, weight loss trajectories, and tolerability profiles between the two, making the cost savings a significant advantage for long-term adherence

This unique formulation combines three synergistic components: Tirzepatide mimics two key hormones (GLP-1 and GIP) that control appetite, slow digestion, and improve insulin sensitivity